Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Luteal Phase After GnRHa Trigger - a Proof of Concept Study
Brief Summary: The purpose of this study is to investigate levels of progesterone in the luteal phase after various stimulations in the follicular phase and treatment with GnRH antagonist protocol followed by GnRHagonist as induction of ovulation.


Options:
A: Inclusion Criteria:

1. Pre-menopausal females between the ages of 18 and 42 years
2. Diagnosed with polycystic ovary syndrome (PCOS), using criteria adopted as the 2003 Rotterdam PCOS Consensus (2 out of 3, excluding other etiologies \[congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome\])

   * Oligo- or anovulation
   * Clinical and/or biochemical signs of hyperandrogenism
   * Polycystic ovaries
3. Body mass index (BMI) of 18-39
4. Early follicular phase (Day 3) follicle stimulating hormone (FSH) \< 15 IU/L and estradiol (E2) within normal limits
5. Documented history of infertility (e.g., unable to conceive for at least one year, or for 6 months for women \> 38 years of age, or bilateral tubal occlusion or absence, or male factor but excluding severe male factor requiring invasive or surgical sperm retrieval. Donor sperm may be used.)
6. Transvaginal ultrasound at screening consistent with findings adequate for assisted reproductive technology (ART) with respect to uterus and adnexa
7. Signed informed consent

Exclusion Criteria:

1. Gestational or surrogate carrier, donor oocyte
2. Presence of any clinically relevant systemic disease (e.g., uncontrolled thyroid or adrenal dysfunction, an organic intracranial lesion such as a pituitary tumor, insulin-dependent diabetes mellitus, uterine cancer)
3. Surgical or medical condition which, in the judgment of the Investigator or Sponsor, may interfere with absorption, distribution, metabolism, or excretion of the drugs to be used
4. Two or more previous failed in vitro fertilization (IVF) cycles or in vitro fertilization (IVF)/assisted reproductive technology (ART) failure due to a poor response to gonadotropins, defined as development of 2 mature follicles
5. History of recurrent pregnancy loss, defined as more than two clinical losses
6. Presence of abnormal uterine bleeding of undetermined origin
7. Current or recent substance abuse, including alcohol or smoking \> 10 cigarettes per day
8. Refusal or inability to comply with the requirements of the Protocol for any reason, including scheduled clinic visits and laboratory tests
9. Participation in any experimental drug study within 30 days prior to Screening
10. Severe male factor requiring invasive or surgical sperm retrieval (e.g., microsurgical epididymal sperm aspiration \[MESA\], testicular sperm extraction \[TESE\])
11. Prior hypersensitivity to any of the protocol drugs
B: Inclusion Criteria:

* women from the age of 25 up to 40
* Serum-FSH and serum-LH levels under 12 IU/L
* Length of period between 25 and 34 days
* BMI between 18 and 30

Exclusion Criteria:

* less than 2 ovaries
* uterine abnormalities
* PCOS or UL-PCO (more than 11 follicles over 12 mm in 1 ovary
C: Inclusion Criteria:

* Age ≤ 36 years
* Body mass index between 18 and 29
* Presence of both ovaries
* Basal levels of estradiol (≤ 80 pg/ml) and progesterone (≤ 1.6ng/ml) on day one of the cycle and a day three FSH level of \<12IU/L
* Patients can enter the study only once.
* Only the first IUI attempt will be included ( at the 2nd and 3 rd attempt progesterone could be administrated if it is necessary but these attempts will be excluded from the study)
* Normal HSG (maximum 3 months prior starting the stimulation).
* Donor sperm can be included

Exclusion Criteria:

* Polycystic ovarian syndrome (Rotterdam criteria)
* Endometriosis(≥AFS III)
D: Inclusion Criteria:

* 45-55 or 70-80 years old
* History of natural menopause defined by the absence of menses for at least 12 months (or history of surgical menopause defined as bilateral oophorectomy) and a FSH level \>26 IU/L
* On no hormonal medication or herbal supplements and/or over the counter menopause therapy for a minimum of 2 months prior to study
* Normal thyroid stimulating hormone, prolactin, factor V Leiden, and complete blood count - Normal blood urea nitrogen and creatinine (\< 2 times the upper limit of normal)
* basal metabolic index ≤ 30
* Non-smokers or smoke less than 10 cigarettes/day

Exclusion Criteria:

* Absolute contraindications to the use of physiologic replacement doses of estrogen, including a negative screening mammogram within the past 24 months
* History of coronary artery disease
* On medications thought to act centrally on the GnRH pulse generator
* Past history of hypersensitivity or allergy to narcotics, vancomycin, muscle relaxants, aspirin, and/or anaphylactic reaction(s) to other drugs
* Prior history of breast cancer and/or blood clots

Answer: B